2023年第2版NCCN肝细胞癌临床实践指南解读  

Interpretation of NCCN clinical practice guidelines for hepatocellular carcinoma, version 2.2023

作　　者：施纯朝 王葵 SHI Chunchao;WANG Kui(Department of Hepatic SurgeryⅡ,Third Affiliated Hospital of Naval Military Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第三附属医院肝外二科,上海200433

出　　处：《外科理论与实践》2024年第2期99-105,共7页Journal of Surgery Concepts & Practice

摘　　要：美国国家综合癌症网络(NCCN)作为肿瘤领域世界权威性非盈利联盟组织,每年持续更新多种恶性肿瘤的临床实践指南,已成为全球肿瘤学临床实践指南的基准。目前NCCN肝细胞癌(HCC)临床实践指南已更新至2023年V2版,与2023年V1版相比,主要是讨论部分内容的更新。从2023.V1版开始,NCCN将HCC与胆管癌的临床实践指南拆分,更新主要集中于肿瘤筛查、诊断、手术、辅助治疗、局部治疗、系统治疗等方面,并首次新增分子检测。故在2023.V2版中将2023.V1版的更新再次着重列出。本文就最新指南和这两版的更新内容进行重点解读。The National Comprehensive Cancer Network(NCCN),as the world's leading non‑profit consortium in the field of oncology,continues to update clinical practice guidelines for multiple malignancies annually and has become a benchmark for clinical practice guidelines in oncology worldwide.Currently,the NCCN clinical practice guidelines for hepatocellular carcinoma have been updated to version 2.2023,as compared with version 1.2023 of its main updates for the content of the discussion section.The NCCN guidelines for hepatobiliary cancers have been reorganized to separate guidelines for biliary tract cancers and hepatocellular carcinoma since version 1.2023.The main updates focus on tumor screening,diagnosis,surgery,adjuvant therapy,locoregional therapy,systemic therapy,and so on.The molecular testing was added for the first time.Therefore,the updates of version 1.2023 were highlighted again in the new version 2.2023.This article interpreted the new guidelines and focused on the aspects of updates.

关 键 词：肝细胞癌 美国国家综合癌症网络 指南 更新 

分 类 号：R735.7[医药卫生—肿瘤]